Tango Therapeutics TNGX Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's available-for-sale debt securities - unrealized loss position (<12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's available-for-sale debt securities - unrealized loss position (<12 months)?
- Tango Therapeutics (TNGX) reported available-for-sale debt securities - unrealized loss position (<12 months) of $154.03M in Q1 2026.
- How has Tango Therapeutics's available-for-sale debt securities - unrealized loss position (<12 months) changed year-over-year?
- Tango Therapeutics's available-for-sale debt securities - unrealized loss position (<12 months) increased by 170.9% year-over-year, from $56.85M to $154.03M.
- What is the long-term trend for Tango Therapeutics's available-for-sale debt securities - unrealized loss position (<12 months)?
- Over 3 years (2021 to 2024), Tango Therapeutics's available-for-sale debt securities - unrealized loss position (<12 months) has grown at a -48.1% compound annual growth rate (CAGR), from $329.71M to $46.02M.